Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LLEWELYN J RAO

Allopathic & Osteopathic Physicians Ophthalmology Retina Specialist

NPI
1518165448
CMS profile
158855
Location
BEACHWOOD, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$5,274.24

55 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $2,115.00 1
Food and Beverage $1,769.24 53
Honoraria $1,390.00 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LLEWELYN J RAO

NPI 1518165448 · CMS profile ID 158855

Allopathic & Osteopathic Physicians / Ophthalmology / Retina Specialist

BEACHWOOD, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1518165448?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LLEWELYN J RAO, NPI 1518165448, CMS profile ID 158855. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518165448?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). LLEWELYN J RAO, NPI 1518165448, CMS profile ID 158855. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518165448?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
LLEWELYN J RAO, NPI 1518165448, CMS profile ID 158855, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1518165448?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

55 matching records · $5,274.24 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 55 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–55 of 55.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Dutch Ophthalmic, USA $132.8702/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154792328 CMS
ABBVIE INC. $33.6002/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105376294 CMS
Genentech USA, Inc. $27.1101/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133055460 CMS
Alimera Sciences, Inc. $18.0501/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092837827 CMS
Coherus Biosciences Inc. $20.7201/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147277910 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,572.31 31
PY2020 $1,513.53 17
PY2021 $24,950.22 47
PY2022 $18,487.39 50
PY2023 $4,318.11 53
PY2024 $5,274.24 55
PY2025 $1,140.32 40

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $89,333.58 95
PY2024 Principal investigator $126,437.40 28
PY2023 Principal investigator $128,897.58 9
PY2022 Principal investigator $241,487.18 20
PY2021 Principal investigator $73,895.13 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

95 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 11/07/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363572
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 11/07/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363574
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 11/07/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363576
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 11/07/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363578
Principal investigator 1 Apellis Pharmaceuticals, Inc. $577.00 11/07/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363590
Principal investigator 1 Apellis Pharmaceuticals, Inc. $577.00 11/07/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363592
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 11/07/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363594
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 11/07/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363596
Principal investigator 1 Apellis Pharmaceuticals, Inc. $577.00 11/07/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363598
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 11/07/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363600
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 11/07/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363602
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 11/07/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363612
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,439.00 08/01/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250363560
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,720.00 08/01/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250363562
Principal investigator 1 Apellis Pharmaceuticals, Inc. $577.00 07/23/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363432
Principal investigator 1 Apellis Pharmaceuticals, Inc. $577.00 07/23/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363434
Principal investigator 1 Apellis Pharmaceuticals, Inc. $577.00 07/23/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363436
Principal investigator 1 Apellis Pharmaceuticals, Inc. $577.00 07/23/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363438
Principal investigator 1 Apellis Pharmaceuticals, Inc. $577.00 07/23/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363440
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 07/16/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363460
Principal investigator 1 Apellis Pharmaceuticals, Inc. $577.00 07/16/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363462
Principal investigator 1 Apellis Pharmaceuticals, Inc. $577.00 07/16/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363464
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,976.00 06/20/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363536
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 06/20/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363538
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,430.00 06/20/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363540
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,976.00 05/16/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363542
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,976.00 05/16/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363544
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,976.00 05/16/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363546
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 05/16/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363548
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 05/16/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363550
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,430.00 05/16/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363552
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,430.00 05/16/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363554
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,040.00 05/07/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250363514
Principal investigator 1 Apellis Pharmaceuticals, Inc. $11,659.00 04/30/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250363512
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $246.18 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175676
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.88 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175678
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,716.20 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175680
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $309.50 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175682
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.07 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175684
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.07 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175686
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $309.50 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175688
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.07 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175690
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.07 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175692
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.64 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175768
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $239.30 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175770
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $312.06 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175772
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.07 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175774
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.64 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175776
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.07 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175778
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.07 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175780
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $309.50 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175782
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.07 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175784
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $296.54 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175786
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.07 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175788
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.07 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175790
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $314.36 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175792
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.07 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175794
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $246.18 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175796
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.88 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175798
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.07 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175866
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.07 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175868
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $307.60 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175870
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.07 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175872
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.07 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175874
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $314.36 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175876
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.07 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175878
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.07 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175880
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $309.50 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175882
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $296.54 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175884
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.80 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175886
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $316.24 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175888
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.07 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175890
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.07 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175892
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $312.06 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175894
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $239.30 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175896
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.07 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175988
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $316.24 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175990
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $257.52 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175992
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $257.52 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175994
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $263.73 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175996
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.80 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184175998
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.07 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184176000
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $307.60 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184176002
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.07 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184176004
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.07 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184176006
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.80 03/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184176008
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 03/14/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363490
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 03/14/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363492
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 03/14/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363494
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,000.00 03/05/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion No dispute reported 06/30/2026 1184156914
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $650.00 03/05/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion No dispute reported 06/30/2026 1184156936
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 02/19/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363476
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 01/24/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363504
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 01/24/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363506
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 01/24/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363508

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2022 Amount invested $0.00 1
PY2022 Value of interest $20,006.00 1
PY2021 Amount invested $0.00 1
PY2021 Value of interest $20,006.00 1
PY2020 Amount invested $0.00 1
PY2020 Value of interest $20,006.00 1
PY2019 Amount invested $0.00 1
PY2019 Value of interest $20,006.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

4 records · PY2019–2022

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2022 US Retina LLC $0.00 $20,006.00 Shares Physician Covered Recipient No dispute reported 06/30/2026 951869147
PY2021 US Retina LLC $0.00 $20,006.00 Shares Physician Covered Recipient No dispute reported 06/30/2026 856668675
PY2020 US Retina LLC $0.00 $20,006.00 Shares Physician Covered Recipient No dispute reported 06/30/2026 714310975
PY2019 US Retina LLC $0.00 $20,006.00 Shares Physician Covered Recipient No dispute reported 06/30/2026 655842143